Biological Evaluation Plan (BEP) Requirements for MDR 2017/745 Compliance

Executive Summary

In the context of European Medical Device Regulation (MDR) 2017/745 certification, the Biological Evaluation Plan (BEP) has emerged as a high-frequency core document during technical documentation reviews by Notified Bodies. Derived from the EN ISO 10993-1 framework, the BEP is a forward-looking strategic document developed during the design and development phase. Its primary purpose is to systematically plan the demonstration of biological safety for materials in contact with the human body.

A compliant BEP must move beyond a simple “checklist” approach, providing scientific justification for every decision. It serves as a “biological safety argumentation roadmap” that identifies required biological endpoints, assesses existing evidence (such as material equivalence and historical data), and defines the strategy to address any remaining data gaps. Failure to provide a comprehensive, scientifically backed BEP often results in the immediate rejection of technical documentation by notified bodies.

The Core Framework of a BEP

A robust BEP is designed to answer three fundamental questions regarding a medical device:

1. What needs to be proven? Identification of biological endpoints based on the device’s specific contact characteristics.
2. What evidence is already available? Integration of existing material data, scientific literature, historical testing, and information from equivalent devices.
3. What is missing and how will it be addressed? Definition of testing protocols, scientific justifications for exemptions, or the need for further data acquisition.

Mandatory Components for MDR Compliance

To meet the requirements of MDR technical documentation, a BEP must include the following twelve elements:

1. Device and Contact Characteristics

The plan must detail the device’s intended use and categorize its interaction with the patient, including:

• Contact Site: Skin, mucosal membranes, blood, or internal tissues.
• Nature of Contact: Surface contact, external communication, or internal implantation.
• Duration of Contact: Limited, prolonged, or permanent/long-term.
• Target Population: Specific considerations for adults, children, or pregnant women.

2. Material and Manufacturing Information

A comprehensive list of all materials coming into contact with the human body is required. This includes:

• Supplier data and Material Safety Data Sheets (MSDS).
• Detailed manufacturing processes and the use of processing aids, additives, or cleaning agents.
• Sterilization methods and controls for residues.

3. Biological Risk Identification

Following ISO 10993-1 Annex A, the BEP must determine which biological endpoints require evaluation, such as cytotoxicity, sensitization, irritation, systemic toxicity, and hemocompatibility.

4. Chemical Characterization Strategy

The document must outline the path for information gathering, prioritizing the following:

• Material equivalence arguments.
• Theoretical “worst-case” assessments.
• Extraction studies (per ISO 10993-18) to minimize unnecessary animal testing.

5. CMR and EDC Screening

Identification and assessment of substances that are Carcinogenic, Mutagenic, or toxic to Reproduction (CMR), as well as Endocrine Disrupting Chemicals (EDC). This includes evaluating if these substances exceed the 0.1% threshold and providing substitution analysis if necessary.

6. Gap Analysis

A systematic review of existing data—including supplier information, literature, and historical reports—to identify discrepancies between available evidence and the required biological endpoints.

7. Testing and Exemption Strategy

The BEP must define which tests (chemical or biological) will be performed. Crucially, every endpoint must have a scientific rationale explaining why a test is being conducted or why an exemption is justified.

8. Toxicological Assessment Plan

Following chemical characterization, the plan must define the risk assessment path according to ISO 10993-17, establishing thresholds such as the Analytical Evaluation Threshold (AET) and Threshold of Toxicological Concern (TTC).

9. Packaging and Storage

Evaluation of packaging materials and their potential impact on device safety, including shelf-life considerations.

10. Risk Management Integration

The BEP must interface with ISO 14971 risk management protocols, clearly defining the criteria for biological risk acceptability.

11. Post-Market Surveillance (PMS)

The plan should outline biological safety indicators for Post-Market Clinical Follow-up (PMCF) and identify specific triggers (such as adverse event trends) that would require a BEP update.

12. Timelines and Responsibilities

An organized schedule of evaluation activities and the identification of the personnel responsible for each phase.

Strategic Guidance for Compliance

Prioritization of Chemical Characterization

Manufacturers are encouraged to prioritize material equivalence or chemical analysis over biological testing. This approach aligns with the goal of reducing unnecessary animal testing while maintaining rigorous safety standards.

Personnel Qualifications

Notified Bodies scrutinize the qualifications of the individuals involved in the BEP. The document should be authored and reviewed by professionals with specialized backgrounds in toxicology and materials science.

Dynamic Maintenance

The BEP is not a static document. It must be reviewed and updated in response to several triggers:

• Design changes or material substitutions.
• Changes in suppliers.
• Emerging trends in adverse events or post-market data.

Scientific Reasoning vs. Checklists

The 2025 version of ISO 10993-1 explicitly opposes the mindless application of test checklists. Every decision within the BEP—whether to test or to waive—must be supported by a robust scientific rationale. The BEP is not expected to contain raw test data; rather, it is the strategic framework that demonstrates “systematic thinking” regarding biological risks.